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Chronic low-grade peripheral inflammation is associated with ultra resistant 
schizophrenia. Results from the FACE-SZ cohort.  
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Abstract  
Introduction. A high rate of patients with schizophrenia (SZ) does not sufficiently 
respond to antipsychotic medication, which is associated with relapses and poor 
outcomes. Chronic peripheral inflammation has been repeatedly associated with 
schizophrenia risk and particularly to poor responders to treatment as usual with 
cognitive impairment in SZ subjects. The objective of present study was to confirm if 
ultra resistance to treatment in schizophrenia (UTRS) was associated to chronic 
peripheral inflammation in a non-selected sample of community-dwelling outpatients 
with schizophrenia.  
Methods. Participants were consecutively included in the network of the FondaMental 
Expert Centers for Schizophrenia and received a thorough clinical assessment, 
including recording of current treatment. Current psychotic symptomatology was 
evaluated by the Positive and Negative Syndrome scale for Schizophrenia (PANSS). 
UTRS was defined by current clozapine treatment+ PANSS total score≥70.  
Functioning was evaluated by the Global Assessment of Functioning scale. High 
sensitivity CRP (hs-CRP) was measured for each participant as a proxy to define 
peripheral low-grade inflammation.  
Results. 609 stabilized community-dwelling SZ subjects (mean age=32.5 years, 
73.6% male gender) have been included. 60(9.9%) patients were classified in the 
UTRS group. In multivariate analyses, UTRS has been associated independently with 
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chronic peripheral inflammation (OR=2.6 [1.2-5.7], p=0.01), illness duration 
(0R=1.1 [1.0-1.2], p=0.02) and impaired functioning (OR  = 0.9 [0.9-0.9], 
p=0.0002) after adjustment for age, sex, current daily tobacco smoking, 
metabolic syndrome and antidepressant consumption. 
Conclusion. Peripheral low-grade inflammation is associated with UTRS. Future 
studies should explore if anti-inflammatory strategies are effective in UTRS with 
chronic low-grade peripheral inflammation. 
 
Keywords: resistant schizophrenia, inflammation, functioning 
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Introduction 
 
For most affected individuals, schizophrenia (SZ) is a chronic and disabling 
disorder. One of the most important predictors of relapse in schizophrenia is the 
response to antipsychotic medication, known to be highly variable in schizophrenia. 
The definition of treatment resistance remains controversial in spite of its importance 
((Howes et al., 2017a), for review see (Peuskens, 1999)). One in three patients is 
classified as treatment-resistant schizophrenia (Lindenmayer et al., 2009; Meltzer, 
1997). Clozapine is still considered to date as the most effective antipsychotic (Sultan 
et al., 2017) and a meta-analysis confirmed the largest effect size among the newer 
generation antipsychotics (Leucht et al., 2013). Since the pivotal study by Kane et al. 
(Kane et al., 1988) found that about a third of stringently defined treatment-resistant 
patients responded to clozapine, it has been the gold standard medication in this 
specific population and is now recommended in international therapeutic guidelines 
(Abidi et al., 2017; Hasan et al., 2015, 2013; Howes et al., 2017b; Keating et al., 
2017; Leucht et al., 2015; Lo et al., 2016; Remington et al., 2017; Samalin et al., 
2013; Stahl et al., 2013). However, 40% still remain classified as resistant to 
clozapine, which has been called “ultra resistance to treatment in schizophrenia” 
(UTRS) (Siskind et al., 2017). The pathophysiological bases of UTRS remain largely 
to be elucidated (Suzuki et al., 2011).  
Among the factors associated with resistance to antipsychotics, chronic low-
grade peripheral inflammation has received increased interest during the last decade 
(Fond et al., 2015; Khandaker et al., 2015). Inflammatory blood markers have been 
recently shown to predict poor treatment response to antipsychotics ((Fernandez-Egea 
et al., 2016; Mondelli et al., 2015; Nishimon et al., 2017), for review see (Fond et al., 
2015)). In clinical practice, peripheral low-grade inflammation is measured by an 
elevated blood level of highly sensitive C-reactive protein (hs-CRP) (Lopresti et al., 
2014). CRP is a common final denominator in the inflammation cascade (Lopresti et 
al., 2014) and has been associated with increased SZ risk in recent meta-analyses 
(Fernandes et al., 2016; Inoshita et al., 2016). High blood CRP level has also been 
associated with cognitive impairment, a major source of disability in schizophrenia 
(Bulzacka et al., 2016), and a large set of data has confirmed that anti-inflammatory 
add-on strategies are effective in improving SZ symptomatology (Fond et al., 2014; 
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Nitta et al., 2013; Sommer et al., 2013). If UTRS is associated with peripheral low-
grade inflammation, it may be reasonably hypothesized that anti-inflammatory 
strategies should be useful to improve the outcomes of this specific population.  
 
The objectives of the present study were to determine the prevalence of UTRS 
in a large non-selected sample of stabilized community-dwelling SZ outpatients, and 
to determine whether UTRS was associated with peripheral low-grade inflammation. 
 
Population and methods 
 
Study design 
The FACE-SZ (FondaMental Academic Centers of Expertise for 
Schizophrenia) cohort is based on a French national network of 10 Schizophrenia 
Expert Centers (Bordeaux, Clermont-Ferrand, Colombes, Créteil, Grenoble, Lyon, 
Marseille, Montpellier, Strasbourg, Versailles), set up by a scientific cooperation 
foundation in France, the FondaMental Foundation (www.fondation-fondamental.org) 
and pioneered by the French Ministry of Research in order to create a platform that 
links thorough and systematic assessment to research (Schürhoff et al., 2015).  
 
Study population 
Consecutive clinically stable patients (defined by no hospitalization and no 
treatment changes during the 4 weeks before evaluation) with a DSM-IV-TR 
diagnosis of schizophrenia or schizoaffective disorder were consecutively included in 
the study. Diagnosis was confirmed by two trained psychiatrists of the Schizophrenia 
Expert Centres network. All subjects were referred by their general practitioner or 
psychiatrist who subsequently received a detailed evaluation report with suggestions 
for personalized interventions.  
Patients with a history of neurological disorders (including stroke, epilepsy 
and head injury) or all non-psychiatric concurrent illnesses affecting the central 
nervous system and on-going and treated inflammatory disorder such as lupus, 
rheumatoid arthritis or acute infectious disorder were not included in the present study.  
Data collected 
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Patients were interviewed by members of the specialized multidisciplinary 
team of the Expert Center. Diagnoses interviews were carried out by two independent 
psychiatrists according to the Structured Clinical Interview for Mental Disorders 
(SCID 1.0). Information about education, onset and course of the illness, body mass 
index and comorbidities were recorded.  
Schizophrenic symptomatology was assessed using the Positive And Negative 
Syndrome Scale (PANSS) (Kay et al., 1987). Current depressive symptoms were 
evaluated using the Calgary Depression Rating Scale for Schizophrenia (CDRS) 
(Addington et al., 1993). This scale was specifically designed to identify specific 
depressive symptomatology that cannot be related to negative symptoms of 
schizophrenia. Manic symptoms were evaluated using the Young Mania Rating 
Scale (YMRS) (Young et al., 1978). Daily global functioning was evaluated with the 
Global Assessment of Functioning Scale (GAF) (Startup et al., 2002).  Ongoing 
psychotropic treatment was recorded. Alcohol and/or cannabis disorders were defined 
according to the SCID 1.0. Self-reported adherence to pharmacological treatment was 
evaluated using the French translation of the MARS (Misdrahi et al., 2004). 
 
UTRS definition 
 UTRS was defined by current clozapine treatment and a mean PANSS 
score ≥70, which is suggested to correspond to “moderately to severely ill” 
patients (Leucht et al., 2005).  
 
Measurements 
A blood draw for routine blood exam was performed and triglycerides, LDL, HDL 
and total cholesterol as well as glucose (if patients confirmed fasting for at least 
10h) were collected. High sensitivity CRP (hs-CRP) was measured with an assay 
using nephelometry (Dade Behring) blinded to schizophrenia status. Abnormal 
CRP level was defined as >3 mg/L (Emerging Risk Factors Collaboration et al., 
2010).  
 
Metabolic syndrome (MetS) definition 
Sitting blood pressure (BP) and anthropometrical measurements were recorded 
in the Expert Centers. Two BP measurements were made 30 seconds apart in the 
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right arm after the participant had sat and rested for at least 5 minutes. A third 
BP measurement was made only when the first two BP readings differed by 
more than 10 mm Hg. The average of the two closest readings was used in the 
analysis. Waist circumference was measured midway between the lowest rib and 
the iliac crest with the subjects standing. This was performed with a tape 
equipped with a spring-loaded mechanism to standardize tape tension during 
measurement. Body mass index (BMI) was calculated as weight in kilograms 
divided by the square of the height in meters. Overnight fasting blood was 
collected for metabolic profiles analysis. Fasting levels of serum triglyceride (TG) 
and fasting plasma glucose were measured by an automated system, and serum 
high-density lipoprotein cholesterol (HDL-C) level was measured by 
electrophoresis. The diagnosis of metabolic syndrome was defined according to 
the modified criteria of the International Diabetes Federation (IDF) (Alberti et 
al., 2006), which requires the presence of three or more of the following five 
criteria: high waist circumference (>94 cm for men and >80 cm for women), 
hypertriglyceridemia (≥1.7 mM or on lipid lowering medication), low HDL 
cholesterol level (<1.03 mM in men and < 1.29 mM in women), high blood 
pressure (≥ 130/85 mmHg or on antihypertensive medication), high fasting 
glucose concentration (≥ 5.6 mM or on glucose-lowering medication). 
 
Ethical concerns 
The study was carried out in accordance with ethical principles for medical 
research involving humans (WMA, Declaration of Helsinki). The assessment protocol 
was approved by the relevant ethical review board (CPP-Ile de France IX, January 
18th, 2010). All data were collected anonymously. As this study include data coming 
from regular care assessments, a non-opposition form was signed by all participants. 
 
Statistical analysis 
Socio-demographics and clinical characteristics and treatments are 
presented using measures of means and dispersion (standard deviation) for 
continuous data and frequency distribution for categorical variables. The data 
were examined for normal distribution with the Shapiro-Wilk test and for 
homogeneity of variance with the Levene test. Comparisons between ultra 
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resistant and non-ultra resistant individuals regarding demographic, clinical 
characteristics were performed using the chi-square test for categorical 
variables. Continuous variables were analysed with Student t-tests for normally 
distributed data and in case of normality violation, additional Mann-Whitney 
tests were performed to confirm the result.  
Variables with P values < 0.20 in univariate analysis were included in the 
multivariate logistic regression model of factors associated with ultra resistant 
schizophrenia. Sex and age were forced into the final model as confounding 
factors. This study was a confirmatory analysis. No correction for multiple 
testing has therefore been carried out, which is consistent with 
recommendations (Bender and Lange, 2001). Analyses were conducted using 
SAS (release 9.3; SAS Statistical Institute, Cary, NC). All statistical tests were two-
tailed, with α level set at 0.05. 
 
Results 
 
609 stabilized community-dwelling SZ subjects (mean age=32.5 years, 73.6% 
male gender) have been included. Overall, 60(9.9%) patients were classified in the 
UTRS group (table 1). UTRS has been significantly associated with positive, negative 
and cognitive scores (all p<0.0001), with excitement score (p=0.003) but not with 
depressive score (p=0.08). Compared to non-UTRS, patients of the UTRS group were 
found to have higher illness duration (13.0 vs. 10.6 years, p=0.01), more frequently 
paranoid delusion (56.9% vs 53.1%, p=0.002), grandiosity delusion (23.4% vs. 
10.6%, p=0.009), mystic delusion (23.1% vs.11.7%, p=0.02), auditory hallucinations 
(p=0.02) and disorganized behavior (43.9% vs. 25.2%, p=0.005). No difference on 
catatonia, somatic delusion, guilty delusion, erotomania, jealousy delusion, reference 
delusion, visual and cenesthetic hallucinations, avolia, alogia and blunted affect has 
been found (all p>0.05). In the present study, no significant difference of hs-CRP 
levels has been found between the subgroup of clozapine-treated non-UTRS 
group and UTRS group (all being administered clozapine by definition) (44.4% 
vs. 46.3%, p=0.88). 
In multivariate analyses, UTRS has been associated independently with 
chronic peripheral inflammation (OR=2.6 [1.2-5.7], p=0.01), impaired functioning 
 10 
(OR  = 0.9 [0.91-0.97], p=0.0002) and illness duration (OR= 1.1 [1.0-1.2], p=0.02) 
after adjustment for age, sex, current daily tobacco smoking, metabolic syndrome and 
antidepressant consumption. The mean CRP levels in UTRS and non-UTRS groups 
were presented in figure 1. 45 patients (8.2%) received clozapine treatment without 
being ultra treatment resistant. No difference of clozapine blood levels has been found 
between UTRS and no UTRS groups (mean 523.7 mg/mL (sd=320) in clozapine non-
remitters vs. 460.0 (sd=380.7) in clozapine remitters, p=0.56). Antipsychotic 
consumption was not included in the multivariate model because it was not 
significantly associated with UTRS in univariate analysis. However, forcing 
antipsychotic consumption in the model did not change the results (hsCRP OR =2.1 
[1.0-4.2], p=0.04). 
 
 
 
Discussion 
Our major findings may be summarized as follows: in a large non-selected 
community-dwelling sample of 609 SZ subjects, UTRS has been identified in almost 
10% of the subjects and was independently associated with chronic peripheral 
inflammation and impaired functioning.  
Almost 10% of our sample has been identified as UTRS. This is consistent 
with previous data mentioned in the rationale, which have suggested that one third of 
the patient were treatment resistant and 40% of them (=12%) were ultra-resistant 
(Siskind et al., 2017).  
UTRS has been associated with impaired functioning in the present study. 
This result confirms the clinical significance of our definition of resistance into 
treatment. UTRS has been extensively suggested as a separate schizophrenia subtype 
and has been associated with a specifically impaired functioning ((Iasevoli et al., 
2016), for review see (Strassnig and Harvey, 2014)).  
UTRS has been shown to be associated with peripheral inflammation for the 
first time in the present study. Some previous studies have yielded indirect clues 
suggesting that abnormal inflammatory markers may predict treatment non-response 
in schizophrenia (Mondelli et al., 2015; Nishimon et al., 2017). Moreover, electro-
convulsive therapy, a treatment that has shown effectiveness in resistant 
schizophrenia, has recently shown to modify peripheral inflammatory markers 
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(Kartalci et al., 2016). However, a previous study found no association between 
peripheral inflammation and resistant SZ as defined by clozapine initiation or hospital 
admission due to schizophrenia after having received at least 2 prior antipsychotic 
monotherapy trials of adequate duration) (Horsdal et al., 2017). This discrepancy in 
the results is probably due to the discrepancy between definitions, the present study 
focusing on ultra-resistant SZ and not resistant SZ only. 
Ultra-resistance has been associated with illness duration, which is consistent 
with the results of previous studies supporting the staging model (Ortiz et al., 2017). 
 Altogether, the present results combined with literature data suggest that anti-
inflammatory strategies may be useful in UTRS. Celecoxib has been the most studied 
anti-inflammatory add-on agent in SZ (Sommer et al., 2013). Some trials are ongoing 
to determine if aspirin, N-acetyl-cysteine, minocycline and omega 3 fatty acids may 
be useful anti-inflammatory add-on strategies for this specific population (Cuéllar-
Barboza et al., 2017; Fond et al., 2014; Rossell et al., 2016). 
Limits. These results should be taken with caution. As our study has a cross-
sectional design, no causal link can be definitely inferred. Exercise, diet and gut 
permeability have been suggested as risk factors for peripheral inflammation (Berk et 
al., 2013) and have not been explored in the present study, as well as hormonal 
contraception, omega 3 fatty acid or vitamin D consumption (that may alleviate 
inflammation). As the dosage of the other markers of inflammation is not 
recommended in daily practice in France, other inflammatory markers (including 
interleukin IL-6 and Tumor Necrosis Factor TNF) were not measured in our study. 
Our sample may not be representative of all patients with schizophrenia, particularly 
because institutionalized; hospitalized or very handicapped patients (making thorough 
assessment difficult) were not referred to the expert centers. HsCRP was the only 
inflammatory marker in the present study. Given that clozapine has been 
described to have immunomodulatory effects (Pollmächer et al., 1996), these 
results should be confirmed with other markers like IL-6 and TNF-alpha. 
However, no association between clozapine and increased CRP has been found in 
the present study. 
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Strengths. The use of homogenous and exhaustive standardized diagnostic 
protocols across the centers and inclusion of a large number of potential confounding 
factors in the multivariate analysis (socio-demographic variables, psychotic and mood 
symptomatology, adherence to treatment, addictive behaviors) may be mentioned in 
the strengths of the present work. In the end, our national multi-centric sample of SZ 
patients referred to the Expert Centers may be underscored as another strength.  
 
Conclusion. UTRS is independently associated with peripheral low-grade 
inflammation in stabilized SZ community-dwelling subjects. Future studies 
should explore if anti-inflammatory add-on strategies are effective in UTRS.  
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